<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">55352</article-id><article-id pub-id-type="doi">10.7554/eLife.55352</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Type I interferon underlies severe disease associated with Junín virus infection in mice</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-175339"><name><surname>Hickerson</surname><given-names>Brady T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175341"><name><surname>Sefing</surname><given-names>Eric J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175342"><name><surname>Bailey</surname><given-names>Kevin W</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175343"><name><surname>Van Wettere</surname><given-names>Arnaud J</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-175340"><name><surname>Penichet</surname><given-names>Manuel L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-40755"><name><surname>Gowen</surname><given-names>Brian B</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9113-2575</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Animal, Dairy, and Veterinary Sciences</institution>, <institution>Utah State University</institution>, <addr-line><named-content content-type="city">Logan</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">David Geffen School of Medicine</institution>, <institution>University of California, Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-62461"><name><surname>Schoggins</surname><given-names>John W</given-names></name><role>Reviewing editor</role><aff><institution>University of Texas Southwestern Medical Center</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>brian.gowen@usu.edu</email> (BG);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>05</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e55352</elocation-id><history><date date-type="received"><day>21</day><month>01</month><year>2020</year></date><date date-type="accepted"><day>25</day><month>05</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Hickerson et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Hickerson et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-55352-v1.pdf"/><abstract><p>Junín virus (JUNV) is one of five New World mammarenaviruses (NWMs) that cause fatal hemorrhagic disease in humans and is the etiological agent of Argentine hemorrhagic fever (AHF). The pathogenesis underlying AHF is poorly understood; however, a prolonged, elevated interferon-a (IFN-a) response is associated with a negative disease outcome. A feature of all NWMs that cause viral hemorrhagic fever is the use of human transferrin receptor 1 (hTfR1) for cellular entry. Here, we show that mice expressing hTfR1 develop a lethal disease course marked by an increase in serum IFN-a concentration when challenged with JUNV. Further, we provide evidence that the type I IFN response is central to the development of severe JUNV disease in hTfR1 mice. Our findings identify TfR1-mediated entry and the type I IFN response as key factors in the pathogenesis of JUNV infection in mice.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R56 AI13646</award-id><principal-award-recipient><name><surname>Gowen</surname><given-names>Brian B</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI14110</award-id><principal-award-recipient><name><surname>Gowen</surname><given-names>Brian B</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 CA196266</award-id><principal-award-recipient><name><surname>Penichet</surname><given-names>Manuel L</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006630</institution-id><institution>Utah State University</institution></institution-wrap></funding-source><award-id>Graduate Research and Creative Opportunities grant</award-id><principal-award-recipient><name><surname>Hickerson</surname><given-names>Brady T</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Manuel L Penichet, is a shareholder of Klyss Biotech, Inc. The Regents of the University of California licensed Dr. Penichet's technology to this firm. The author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal procedures complied with USDA guidelines and were conducted at the AAALAC-accredited laboratory animal research facilities at Utah State University under protocol #10034, approved by the Utah State University Institutional Animal Care and Use Committee.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript.</p></sec><supplementary-material><ext-link xlink:href="elife-55352-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>